Virus, Vessel, Victory: A Novel Approach to Tumor Killing

Yonina Bykov; Dmitriy Zamarin

doi:10.1158/1078-0432.CCR-18-3441

Virus, Vessel, Victory: A Novel Approach to Tumor Killing

Clin Cancer Res. 2019 Mar 1;25(5):1446-1448. doi: 10.1158/1078-0432.CCR-18-3441. Epub 2018 Dec 10.

Authors

Yonina Bykov¹, Dmitriy Zamarin^{2

3

4

5}

Affiliations

¹ Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York.
² Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York. zamarind@mskcc.org.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Medicine, Weill Cornell Medical College, New York, New York.
⁵ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.

Abstract

Ovarian cancer is intimately dependent on aberrant tumor vasculature. A unique therapeutic approach combining a systemic oncolytic virus with a novel vascular-normalizing agent in ovarian cancer demonstrates the potential to enhance antitumor efficacy through improved delivery of the virus and enhanced infiltration of immune cells into the tumors.See related article by Matuszewska et al., p. 1624.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Cell Line, Tumor
Female
Humans
Immunotherapy
Oncolytic Virotherapy*
Oncolytic Viruses*
Ovarian Neoplasms*

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States